Specifically, the observation that pretreatment CD8+PD-1+ TCI was predictive of response is consistent with immune pressure being a determinant of efficacy of this treatment, in line with a recent study in ICB-treated gastric cancer patients reporting a strong association between clinical response to anti-PD-1/PD-L1 and the proportion of CD8+PD-1+LAG3− T cells in proximity of tumor cells42. The gene discussed is PDCD1; the disease is neoplasm.